Navigation Links
Jubilant Enters Research Collaboration With AstraZeneca

NOIDA, India, May 5 /PRNewswire/ --

- Research Collaboration to Provide AstraZeneca With New Preclinical Drug Candidates

Jubilant Organosys Ltd, headquartered in India, announced today that its Bangalore, India, based subsidiary,Jubilant Biosys Ltd, has signed a research collaboration agreement with, AstraZeneca, and focused on delivering novel drug candidates into the international pharmaceutical company's pre-clinical pipeline. Under the shared risk-reward collaboration, which will initially focus on the neuroscience area, Jubilant aims to deliver a steady stream of discovery programs to AstraZeneca.

AstraZeneca will own the compounds developed under the collaboration with worldwide development and commercialization rights. Jubilant will be eligible to receive research funding spanning an initial five-year period. In addition, AstraZeneca will also pay Jubilant success-based development milestones, as well as royalties based on successful global commercialization of any of the compounds.

Commenting on this Collaboration, Mr. Shyam S Bhartia, Chairman & Managing Director and

Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Organosys Ltd, said: "We are very pleased to partner with AstraZeneca, this collaboration will leverage the innovative capabilities of AstraZeneca and Jubilant Biosys in providing a robust global drug discovery model. Through this partnership, Jubilant is confident of contributing to AstraZeneca's preclinical portfolio and anticipates significant rewards from successful downstream milestones. This partnership furthers Jubilant's strategy to be India's largest provider of innovative and integrated pharmaceutical solutions, enabling the global pharmaceutical industry's quest to discover affordable innovative medicines."

Jan Lundberg, Executive Vice-President, Global Discovery, at AstraZeneca says, "This collaboration complements our internal capabilities and increases the capacity of our pre-clinical programs. It is a concrete example of the innovative approaches we are taking to deliver a sustainable Discovery pipeline with a lean and agile organization. Ultimately, this will provide us with more shots on goal as we look to sustain a competitive portfolio and provide meaningful medicines to patients."

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit:

About Jubilant Biosys

Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd.,provides integrated drug discovery and development solutions to the global pharmaceutical industry. Jubilant Biosys has an integrated state of the art facility in Bangalore. The Center houses over 300 scientists specializing in multiple disciplines to include Discovery biology, medicinal chemistry, structural biology, pharmacology, toxicology, pharma chem, molecular modeling, crystallography and information technology supporting discovery efforts.

For more information please visit:

About Jubilant Organosys

Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies out of India. The company has a presence across the pharmaceutical value chain for products and services such as proprietary products ,exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables (liquids and lyophilized) products, non-steriles (ointments, creams and liquid) and radiopharmaceuticals, drug discovery services, medicinal chemistry services, clinical research services, generic dosage forms and healthcare. Jubilant Organosys has geographically diversified manufacturing facilities at ten locations worldwide. Together, these help Jubilant cater to 150 customers across more than 50 countries around the world.For more information please visit:


Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Organosys may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company's filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

    For further information contact:

    For Media:
    Seema Ahuja
    Jubilant Organosys Limited
    Ph:     +91-120-4361062
    Mobile: +91-9810631779

    For Business Queries: Europe and APAC:
    Saurabh Kapure
    Senior Manager Business Development
    Jubilant Biosys and Jubilant Chemsys Ltd.
    Direct: +91-80-6662-8852

    For Investors:
    Deepak Malik
    Jubilant Organosys Limited
    Tel: +91-120-4361114
    Fax: +91-120-2516629

    For Business Queries: USA
    Corey Jacklin
    Director, Business Development
    Jubilant Biosys
    Tel: +1-215-369-0965

SOURCE Jubilant Organosys Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
2. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
3. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
4. Another LNA-based RNA Inhibitor Enters Clinical Trials
5. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
6. ESBATechs Antibody Fragment Enters Phase Ib/IIa in Ophthalmology
7. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
8. ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
9. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
10. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
11. Pharmaleads Lead Candidate for Pain, PL37, Enters Phase I
Post Your Comments:
(Date:11/24/2015)... The hope of bearing a ... IVF cycles. After failure of over 15 IVF cycles, ... all hopes that she would be able to conceive ever. But finally optimism prevailed as ... failure of over 15 IVF cycles. ... take one last attempt with Gaudium IVF Center in ...
(Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
(Date:11/24/2015)... 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the ... that the first patient has been enrolled in ESSA,s ... for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States and ... clinical trial, ESSA intends to demonstrate the safety, tolerability, ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... 24, 2015 , ... In response to recent news highlighting Oxycodone fraud, Novus ... in the United States grew 400 percent between 1999 and 2010, far more than ... 37 percent of all fatal drug overdoses. (1) , While oxycodone and the extended ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Serenity Point ... a series of recent video interviews with some of the staff members at their ... the residential treatment facility, as well as some of the things that make their ...
(Date:11/24/2015)... ... 2015 , ... Chiropractic student Katie Benson received a $2,500 ... Park, Kansas. Benson, a fifth-trimester student in the university’s College of Chiropractic, accepted ... 16. , “Katie is very excited and greatly appreciative to receive the Standard ...
(Date:11/24/2015)... ... November 24, 2015 , ... Autism Speaks, the world’s leading autism science and ... media and the generosity of people around the world. On December 1, supporters can ... give – and share the personal stories behind those gifts. , Just as ...
(Date:11/24/2015)... ... November 24, 2015 , ... World ... Fragrance by Marcelle, a cosmetic invention which offers a combination of natural essential ... in the US is worth $3 billion annually," says Scott Cooper, CEO and ...
Breaking Medicine News(10 mins):